Asahi Kasei’s Hovilpri is now approved for treating lesions caused by herpes simplex virus infection. This daily pill came from the $919 million acquisition of AiCuris Anti-Infective Cures.
The FDA does more than screen for drug safety and efficacy; it also protects the public against sensational and unproven claims. It's a reality underscored by an intriguing herpes vaccine company charting its own regulatory course.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.